Portfolio News
Sofinnova Crossover
AstraZeneca closes acquisition of Amolyt Pharma
Lyon, France, and Cambridge, MA, July 15, 2024 — Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed.
The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone (PTH) production results in significant dysregulation of calcium and phosphate, which can lead to life-altering symptoms and complications, including chronic kidney disease. This programme, together with Amolyt’s talented team, expertise, and earlier pipeline, will enable Alexion’s expansion into rare endocrinology.
Under the terms of the definitive agreement, AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.
About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. To learn more, visit https://amolytpharma.com or follow us on Twitter and LinkedIn.
Amolyt Contact:
Patrick Loustau
Chief Business Officer
ploustau@amolyt.com
Media inquiries:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Related News
Asahi Kasei completes the recommended public cash offer and becomes the owner of 93.30 per cent of all shares in Calliditas
AFYREN announces signing of new commercial contract with US nutraceutical maker
HighLife receives ISO 13485 certification of its quality management system
Mediar Therapeutics initiates second clinical program in portfolio of novel first-in-class antibodies designed to halt fibrosis
Video: Sofinnova Partners 2024 annual general meeting